ストックスクリーナーアプリを入手
38.56
4.15%
-1.67
前日終値:
$40.23
開ける：
$40.04
24時間の取引高:
1.28M
Relative Volume:
1.59
時価総額：
$1.88B
収益：
$140.49M
当期純損益:
$-153.49M
株価収益率:
-14.00
EPS:
-2.7551
ネットキャッシュフロー:
$-175.90M
1週間 パフォーマンス:
+1.42%
1か月 パフォーマンス:
+37.71%
6か月 パフォーマンス:
+81.46%
1年 パフォーマンス:
+163.39%
1日の値動き範囲:
$38.27
$40.35
1週間の範囲:
$36.55
$40.35
52週間の値動き範囲:
$13.79
$40.35
Urogen Pharma Ltd Stock (URGN) Company Profile
Compare URGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
38.56 | 1.88B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Jefferies | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-06-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-19 | 再開されました | Ladenburg Thalmann | Buy |
| 2024-08-22 | 開始されました | Guggenheim | Buy |
| 2023-02-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-27 | 開始されました | Berenberg | Buy |
| 2020-04-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-09 | 開始されました | National Securities | Neutral |
| 2019-05-30 | 開始されました | JP Morgan | Neutral |
| 2019-05-29 | 開始されました | Goldman | Neutral |
| 2019-01-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-04-04 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-11-15 | 繰り返されました | Oppenheimer | Outperform |
| 2017-11-15 | ダウングレード | Raymond James | Outperform → Mkt Perform |
すべてを表示
Urogen Pharma Ltd (URGN) 最新ニュース
Form 4 Urogen Pharma Ltd For: 10 July By Investing.com - Investing.com Nigeria
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares - Investing.com
UroGen Pharma (URGN) CMO Mark Schoenberg sells 10,000 shares via Rule 10b5-1 plan - Stock Titan
Is UroGen Pharma (URGN) Undervalued Following FDA Clearance For UGN 501? - Sahm
(URGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial - simplywall.st
Form 144 UroGen Pharma Ltd. For: 9 July By Investing.com - Investing.com Nigeria
Affiliate files Form 144: UroGen (NASDAQ: URGN) sells two 10,000-share blocks - Stock Titan
Urogen Pharma stock hits 52-week high at $39.59 - Investing.com
Urogen Pharma stock hits 52-week high at $39.59 By Investing.com - Investing.com Canada
Urogen’s UGN-501 gains IND clearance for bladder cancer - BioWorld News
H.C. Wainwright reiterates UroGen Pharma stock rating on FDA clearance By Investing.com - Investing.com Canada
Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen - ChartMill
Bladder Cancer Oncolytic Virus UGN-501 Cleared by FDA for Phase 1 Trials This Fall - Tech Times
UroGen Pharma secures FDA IND clearance for UGN-501 - grafa.com
UroGen Pharma (URGN) Receives FDA Clearance for IND of UGN-501 - GuruFocus
UroGen receives FDA clearance for bladder cancer trial By Investing.com - Investing.com South Africa
UroGen receives FDA clearance for bladder cancer trial - Investing.com
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer - The Manila Times
UroGen wins FDA clearance to test bladder cancer virus in Phase 1 - Stock Titan
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
UroGen Pharma Ltd focuses on bladder cancer therapies as investors watch long-term prospects - ad-hoc-news.de
URGN stock stays tied to UroGen Pharma's pipeline - ad-hoc-news.de
UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar - Sahm
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? - The Motley Fool
UroGen Pharma (URGN) Surges 4.24% as Shares Approach Key Resistance LevelCombination Correction - dars.gov.et
UroGen Pharma stock consolidates below 52-week high amid sustained bullish momentum - Traders Union
UroGen Pharma edges higher to $34.88 as leadership highlights integrity focus, UroGen Pharma - Traders Union
Urogen Pharma stock hits 52-week high at 36.12 USD By Investing.com - Investing.com Nigeria
Urogen Pharma stock hits 52-week high at 36.12 USD - Investing.com
Price to book forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
(URGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Price to book forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to earnings forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to sales forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to book forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
UroGen settles with Teva over Jelmyto patent dispute - MSN
Enterprise value to revenue forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to earnings forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
Enterprise value to EBIT forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Enterprise value to EBIT forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Enterprise value to EBITDA forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
UroGen Pharma Ltd. Actuals & Estimates (NASDAQ:URGN) - TradingView
URGN Forecast — Price Target — Prediction for 2027 - TradingView
Urogen pharma CMO Mark Schoenberg sells $350,100 in shares By Investing.com - Investing.com Nigeria
Form 4 Urogen Pharma Ltd For: 24 June By Investing.com - Investing.com Australia
Urogen pharma CMO Mark Schoenberg sells $350,100 in shares - Investing.com
Urogen Pharma Ltd (URGN) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):